0000950170-25-079292.txt : 20250529 0000950170-25-079292.hdr.sgml : 20250529 20250529213117 ACCESSION NUMBER: 0000950170-25-079292 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250527 FILED AS OF DATE: 20250529 DATE AS OF CHANGE: 20250529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Encrantz Staffan CENTRAL INDEX KEY: 0001870875 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40587 FILM NUMBER: 251006028 MAIL ADDRESS: STREET 1: C/O SIGHT SCIENCES, INC. STREET 2: 4040 CAMPBELL AVENUE, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sight Sciences, Inc. CENTRAL INDEX KEY: 0001531177 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 800625749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4040 CAMPBELL AVE, STREET 2: SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: (415) 889-0550 MAIL ADDRESS: STREET 1: 4040 CAMPBELL AVE, STREET 2: SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2025-05-27 0001531177 Sight Sciences, Inc. SGHT 0001870875 Encrantz Staffan C/O SIGHT SCIENCES, INC. 4040 CAMPBELL AVE., SUITE 100 MENLO PARK CA 94025 true false true false false Common Stock 2025-05-27 4 P false 41346 3.436 A 1070862 D Common Stock 2025-05-28 4 P false 26715 3.516 A 1097577 D Common Stock 2025-05-29 4 P false 60128 3.588 A 1157705 D Common Stock 632456 I See footnote Common Stock 5086920 I See footnote The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $3.29 to $3.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $3.325 to $3.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $3.50 to $3.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Includes (i) 1,140,339 shares of Common Stock and (ii) 17,366 restricted stock units, which are subject to vesting as previously reported. These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any. These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. /s/ Jeremy Hayden, Attorney-in-Fact for Staffan Encrantz 2025-05-29